New 2026 Guidelines: Mastering Prostate Cancer Treatment Sequencing

ADT alone is no longer enough. Evaluate the evidence for early intensification to maximize survival and quality of life in metastatic CSPC Complete the activity & claim CME/NCPD/AAPA credit today: https://bit.ly/4qhXyV7 Through practical case discussions, you’ll see how to interpret molecular and imaging results, apply current evidence to treatment decisions, and anticipate and manage toxicities while engaging patients in shared decision-making. 0:00 – Introduction 1:02 – Prostate cancer overview 2:10 – Case 1: Mr. MK 4:55 – What are the treatment options? 5:22 – Case 1: Mr. MK (cont.) 7:49 – What do you need to determine if this patient is BRCA-positive or BRCA-negative? 10:14 – What is the algorithm for pathology? 11:39 – How do you test? 12:52 – When should you test? 14:32 – Is a single negative tissue test enough? 15:47 – If you get new tissue, should you retest? 16:30 – Can biomarkers change over time? 17:17 – Interdisciplinary collaboration 18:32 – Common adverse events and management: ADT 22:30 – Case 2: Mr. JH 23:35 – How confident can we be in a positive test? 25:50 – Does it matter if an HRR mutation is germline or somatic? 27:05 – How do we know if it is germline or somatic? 28:40 – Biallelic or monoallelic—Does it matter? 29:46 – Does the type of BRCA2 mutation matter? 32:22 – Common adverse events and management: PARP inhibitors 35:37 – Psychosocial impact of prostate cancer treatment 37:03 – Case 3: Mr. BV 41:20 – Late-discovered BRCA2 mutation—Is it too late? 43:22 – Common adverse events and management: ARPIs 49:33 – Key Takeaways Follow us here: Facebook   / i3health   Instagram   / i3health   Soundcloud   / i3-health   X   / i3health   STATEMENT OF NEED Prostate cancer is the most common cancer in men and the second most common cause of cancer death in men, accounting for 30% of new cancer diagnoses and 11% of cancer deaths in males. When diagnosed in early stages, 5- and 10-year survival rates are high; however, 5-year survival remains under 50% if disease is first detected when metastatic (Siegel et al, 2024). The last 15 years have seen significant advances in systemic therapeutic options for prostate cancer, rendering molecular testing necessary for selecting optimal therapy. Improving outcomes for patients relies on collaboration amongst the care team; pathologists have the crucial expertise for interpreting test results, while nurses play a critical role in connecting patients with support and preventing and managing adverse events. In this Virtual Tumor Board Challenge, Stephen Freedland, MD, Professor of Urology at Samuel Oschin Comprehensive Cancer Institute, ‪@cedarssinai‬; Andrés Matoso, MD, Professor of Pathology, Urology, and Oncology at ‪@JohnsHopkinsMedicine‬; and Jennifer Sutton, RN, BS, CCRC, Director of Nursing and Study Operations at START Carolinas, the ‪@STARTResearch‬ Center for Cancer Research, will navigate treatment selection and sequencing in metastatic prostate cancer through patient case studies. DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES Relevant financial relationships exist between the following individuals and ineligible companies: Stephen Freedland, MD, discloses that he has served on an advisory board or panel for Astellas, AstraZeneca, Bayer, Janssen, Merck, Novartis, Pfizer, Sanofi, Sumitomo, and Tolmar; that he has served on a speaker’s bureau for Astellas and Pfizer; and that he has served as a consultant for Astellas, AstraZeneca, Bayer, Janssen, Merck, Novartis, Pfizer, Sanofi, Sumitomo, and Tolmar. Andrés Matoso, MD, discloses that he has served on an advisory board or panel for Lilly and that he has served as a consultant for Compugen and Diagnexia. Jennifer Sutton, RN, BS, CCRC, discloses that she has served on an advisory board or panel for Bayer and Merck; that she has served on a speaker’s bureau for Bayer; and that she has served as a consultant for Janssen. The i3 Health planners, reviewers, and managers have nothing to disclose. i3 Health has mitigated all relevant financial relationships. Supported by educational funding provided by AstraZeneca and Merck Sharpe & Dohme, LLC Aggregate participant data will be shared with commercial supporters of this activity. #prostatecancer #prostatehealth #mced #MCEDs #tumorboard #medicaleducation #tumor #medicaloncology #oncology #cancertreatments #prostatecancertreatment #oncologyeducation #cancertreatments #oncologyeducation #cedarsinai #johnshopkins #nurseeducation #oncologynurse #urology #urologicalhealth